• Cosmos Health advanced its CCX0722 hydrogel weight-management platform into U.S., European, Australian, Canadian patent phases under WO2025108566A1.
• Program reflects more than three years of R&D, moving from concept in 2022 to pilot production, scale-up, final-stage development by February 2025.
• CCX0722 is designed as a non-systemic, capsule-delivered hydrogel that swells more than 100-fold in the stomach to promote satiety.
• June 8, 2026 acquisition of the patent application consolidated full IP ownership, removing licensing fees, royalties, third-party dependencies.
• Management flagged licensing, co-development, strategic partnerships as potential monetization paths as it evaluates commercialization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606251531PRIMZONEFULLFEED9752837) on June 25, 2026, and is solely responsible for the information contained therein.